Peter J. Embí
A5015307002- Electronic Health Records Systems
- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- Health and Medical Research Impacts
- Ethics in Clinical Research
- Health Sciences Research and Education
- COVID-19 Clinical Research Studies
- Biomedical Text Mining and Ontologies
- Health Systems, Economic Evaluations, Quality of Life
- Biomedical and Engineering Education
- Artificial Intelligence in Healthcare and Education
- COVID-19 epidemiological studies
- Machine Learning in Healthcare
- SARS-CoV-2 detection and testing
- Healthcare Systems and Technology
- Data Quality and Management
- COVID-19 and healthcare impacts
- Primary Care and Health Outcomes
- Genetics, Bioinformatics, and Biomedical Research
- Healthcare Policy and Management
- Meta-analysis and systematic reviews
- Big Data and Business Intelligence
- Research Data Management Practices
- Influenza Virus Research Studies
- Chronic Disease Management Strategies
Regenstrief Institute
2017-2025
Vanderbilt University Medical Center
2021-2025
Vanderbilt University
2021-2025
Nashville Oncology Associates
2024
Vanderbilt Health
2024
Indiana University School of Medicine
2018-2023
Indiana University – Purdue University Indianapolis
2017-2023
Intermountain Healthcare
2021-2023
AID Atlanta
2023
Kaiser Permanente Center for Health Research
2023
The growing amount of data in operational electronic health record systems provides unprecedented opportunity for its reuse many tasks, including comparative effectiveness research. However, there are caveats to the use such data. Electronic from clinical settings may be inaccurate, incomplete, transformed ways that undermine their meaning, unrecoverable research, unknown provenance, insufficient granularity, and incompatible with research protocols. quantity real-world nature these provide...
CDC recommends that all persons aged ≥12 years receive a booster dose of COVID-19 mRNA vaccine ≥5 months after completion primary vaccination series and immunocompromised third dose.* Waning protection 2 doses has been observed during the period SARS-CoV-2 B.1.617.2 (Delta) variant predominance† (1-5), but little is known about durability 3 periods Delta or B.1.1.529 (Omicron) predominance. A test-negative case-control study design using data from eight VISION Network sites§ examined...
Estimates of COVID-19 mRNA vaccine effectiveness (VE) have declined in recent months (1,2) because waning induced immunity over time,* possible increased immune evasion by SARS-CoV-2 variants (3), or a combination these and other factors. CDC recommends that all persons aged ≥12 years receive third dose (booster) an ≥5 after receipt the second immunocompromised individuals primary dose.† A BNT162b2 (Pfizer-BioNTech) increases neutralizing antibody levels (4), three studies from Israel shown...
The National COVID Cohort Collaborative (N3C) is a centralized, harmonized, high-granularity electronic health record repository that the largest, most representative COVID-19 cohort to date. This multicenter data set can support robust evidence-based development of predictive and diagnostic tools inform clinical care policy.
Immunocompromised persons, defined as those with suppressed humoral or cellular immunity resulting from health conditions medications, account for approximately 3% of the U.S. adult population (1). adults are at increased risk severe COVID-19 outcomes (2) and might not acquire same level protection mRNA vaccines do immunocompetent (3,4). To evaluate vaccine effectiveness (VE) among immunocompromised adults, data VISION Network* on hospitalizations persons aged ≥18 years COVID-19-like illness...
The efficacy of the BNT162b2 (Pfizer-BioNTech) vaccine against laboratory-confirmed COVID-19 exceeded 90% in clinical trials that included children and adolescents aged 5-11, 12-15, 16-17 years (1-3). Limited real-world data on 2-dose mRNA effectiveness (VE) persons 12-17 (referred to as this report) have also indicated high levels protection SARS-CoV-2 (the virus causes COVID-19) infection COVID-19-associated hospitalization (4-6); however, VE B.1.1.529 (Omicron) variant duration are...
To estimate the effectiveness of mRNA vaccines against moderate and severe covid-19 in adults by time since second, third, or fourth doses, age immunocompromised status.Test negative case-control study.Hospitals, emergency departments, urgent care clinics 10 US states, 17 January 2021 to 12 July 2022.893 461 (≥18 years) admitted one 261 hospitals 272 department 119 centers for covid-like illness tested SARS-CoV-2.The main outcome was waning vaccine with BNT162b2 (Pfizer-BioNTech) mRNA-1273...
During June-October 2022, the SARS-CoV-2 Omicron BA.5 sublineage accounted for most of sequenced viral genomes in United States, with further diversification through November 2022.* Bivalent mRNA vaccines contain an ancestral strain component plus updated BA.4/BA.5 sublineages. On September 1, a single bivalent booster dose was recommended adults who had completed primary vaccination series (with or without subsequent doses), last administered ≥2 months earlier (1). 13-November 18, VISION...
Persons with moderate-to-severe immunocompromising conditions might have reduced protection after COVID-19 vaccination, compared persons without (1-3). On August 13, 2021, the Advisory Committee on Immunization Practices (ACIP) recommended that adults receive an expanded primary series of 3 doses mRNA vaccine. ACIP followed recommendations September 23, for a fourth (booster) dose and 1, 2022, new bivalent vaccine booster dose, containing components BA.4 BA.5 sublineages Omicron (B.1.1.529)...
On September 1, 2022, CDC's Advisory Committee on Immunization Practices (ACIP) recommended a single bivalent mRNA COVID-19 booster dose for persons aged ≥12 years who had completed at least monovalent primary series. Early vaccine effectiveness (VE) estimates among adults ≥18 showed receipt of provided additional protection against COVID-19-associated emergency department and urgent care visits hospitalizations compared with that in received only doses (1); however, insufficient time...
Importance Recent SARS-CoV-2 Omicron variant sublineages, including BA.4 and BA.5, may be associated with greater immune evasion less protection against COVID-19 after vaccination. Objectives To evaluate the estimated vaccine effectiveness (VE) of 2, 3, or 4 doses mRNA vaccination among immunocompetent adults during a period BA.5 predominant circulation; to relative severity in hospitalized patients across BA.1, BA.2 BA.2.12.1, sublineage periods. Design, Setting, Participants This...
Importance Cefepime and piperacillin-tazobactam are commonly administered to hospitalized adults for empirical treatment of infection. Although has been hypothesized cause acute kidney injury cefepime neurological dysfunction, their comparative safety not evaluated in a randomized clinical trial. Objective To determine whether the choice between affects risks or dysfunction. Design, Setting, Participants The Antibiotic Choice on Renal Outcomes (ACORN) trial compared vs whom clinician...
During June-October 2022, the SARS-CoV-2 Omicron BA.5 sublineage accounted for most of sequenced viral genomes in United States, with further diversification through November 2022.* Bivalent mRNA vaccines contain an ancestral strain component plus updated BA.4/BA.5 sublineages. On September 1, a single bivalent booster dose was recommended adults who had completed primary vaccination series (with or without subsequent doses), last administered ≥2 months earlier (1). 13-November 18, VISION...
Drug repurposing represents an attractive alternative to the costly and time-consuming process of new drug development, particularly for serious, widespread conditions with limited effective treatments, such as Alzheimer's disease (AD). Emerging generative artificial intelligence (GAI) technologies like ChatGPT offer promise expediting review summary scientific knowledge. To examine feasibility using GAI identifying candidates, we iteratively tasked proposing twenty most promising drugs in...
The field of artificial intelligence (AI) has entered a new cycle intense opportunity, fueled by advances in deep learning, including generative AI. Applications recent affect many aspects everyday life, yet nowhere is it more important to use this technology safely, effectively, and equitably than health care. Here, as part the National Academy Medicine's Vital Directions for Health Care: Priorities 2025 initiative, which designed provide guidance on pressing care issues incoming...
Recent advancements of large language models (LLMs) like generative pre-trained transformer 4 (GPT-4) have generated significant interest among the scientific community. Yet, potential these to be utilized in clinical settings remains largely unexplored. In this study, we investigated abilities multiple LLMs and traditional machine learning analyze emergency department (ED) reports determine if corresponding visits were due symptomatic kidney stones. Leveraging a dataset manually annotated...
Objective: Computerized physician documentation (CPD) has been implemented throughout the nation's Veterans Affairs Medical Centers (VAMCs) and is likely to increasingly replace handwritten in other institutions. The use of this technology may affect educational clinical activities, yet little reported regard. authors conducted a qualitative study determine perceived impacts CPD among faculty housestaff VAMC. Design: A cross-sectional was using semistructured interviews with (n = 10) group...
Failure to recruit a sufficient number of eligible subjects in timely manner represents major impediment the success clinical trials. Physician participation is vital trial recruitment but often limited.After 12 months traditional trial, we activated our electronic health record (EHR)-based alert (CTA) system selected outpatient clinics large, US academic care system. When patient's EHR data met criteria during subsequent 4-month intervention period, CTA prompted physician consideration...
Objective Inadequate participant recruitment is a major problem facing clinical research. Recent studies have demonstrated that electronic health record (EHR)-based, point-of-care, trial alerts (CTA) can improve to certain research studies. Despite their promise, much remains be learned about the use of CTAs. Our objective was study whether repeated exposure such leads declining user responsiveness and characterize its extent if present better inform future CTA deployments.
Objectives: Clinical Research Informatics, an emerging sub-domain of Biomedical is currently not well defined. A formal description CRI including major challenges and opportunities needed to direct progress in the field. Design: Given early stage knowledge activity, we engaged a series qualitative studies with key stakeholders opinion leaders determine range facing CRI. These phases employed complimentary methods triangulate upon our findings. Measurements: Study included: 1) group interview...
Large amounts of personal health data are being collected and made available through existing emerging technological media tools. While use these has significant potential to facilitate research, improve quality care for individuals populations, reduce healthcare costs, many policy-related issues must be addressed before their full value can realized. These include the need widely agreed-on stewardship principles effective approaches or eliminate silos protect patient privacy. AMIA's 2012...
TABLE 1. (Continued) Characteristics of COVID-19-like illness hospitalizations* among unvaccinated adults with a SARS-CoV-2 infection occurring 90-179 days before the index test date † and who were fully vaccinated § without previous documented -nine states, ¶ January-September 2021 Characteristic No. (column %) Standardized mean or proportion difference** Unvaccinated Fully Site Columbia University 53 (5) 238 (4) 0.73 HealthPartners 22 (2) 94 (1) Intermountain Healthcare 117 (11) 454 (7)...
Abstract Objective We sought to support public health surveillance and response coronavirus disease 2019 (COVID-19) through rapid development implementation of novel visualization applications for data amalgamated across sectors. Materials Methods developed implemented population-level dashboards that collate information on individuals tested infected with COVID-19, in partnership state local agencies as well systems. The are deployed top a statewide exchange. One dashboard enables...
Our goal is to summarize the collective experience of 15 organizations in dealing with uncoordinated efforts that result unnecessary delays understanding, predicting, preparing for, containing, and mitigating COVID-19 pandemic US. Response involve collection analysis data corresponding healthcare organizations, public health departments, socioeconomic indicators, as well additional signals collected directly from individuals communities. We focused on electronic record (EHR) data, since EHRs...